Gilead Sciences
Every trial this sponsor leads in the registry, and everything it has published.
77 active · 11% of this sponsor’s registry footprint
Not shown above: 1 trial whose condition matched no therapy area.
Trials by phase
Pipeline by phase · 34 drugs in active development
Phase 3 · 10 drugs
Phase 2 · 11 drugs
Phase 1 · 12 drugs
Phase 4 · 1 drug
Not counted above: 1 combination backbone (established drugs used alongside the assets).
Active trials only, code names and brands merged. 459 completed trials are in the counts above but their drugs are not folded into this pipeline.
Disease landscapes · 4 of 10 curated
Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.
Track your drug now for free
We check every one of its trials daily and tell you what moved.
- Status changeStatus moved to completedWas recruiting · always alerts
- Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
- New trialNew trial registered in your scopeFirst posted within 30 days
- Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
- Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English